AusperBio Secures $50 Million Series B+ Financing to Accelerate Clinical Cure for Chronic Hepatitis B

AusperBio (Ausper Biopharma Co., Ltd. and AusperBio Therapeutics Inc.), a clinical-stage innovative drug research and development company, focuses on developing self-innovative targeted delivery small nucleic acid drugs, committed to achieving the goal of clinical cure for chronic hepatitis B.The company announced today the completion of a US$50 million Series B+ financing round.This round of financing was led by a globally renowned industry investment institution, with follow-up investments from Qiming Venture Partners, CDH VGC, Genesis Capital, Origin Capital, Hancong Capital, and Sherpa Healthcare Partners.

This round of financing closely follows the company's Series B financing completed in December 2024, demonstrating investors' strong confidence in AusperBio's leading products, proprietary technology platform, and strategic direction. The funds raised will primarily be used to support the ongoing clinical development of its innovative antisense oligonucleotide drug AHB-137 for the functional cure of chronic hepatitis B (CHB), including the planned Phase II clinical trials to be conducted outside mainland China. Additionally, the funds will be utilized to expand commercial production partnerships and advance the expansion of the product pipeline to support the company’s long-term growth.

Dr. Guozheng Cheng, Co-founder and CEO of AusperBioStated: "We are deeply honored to continuously receive strong support from investors, which fully demonstrates their high recognition of AusperBio's vision and current achievements. This new round of financing will inject strong momentum into the next phase of global development for AHB-137, accelerating the realization of AusperBio's goal to provide innovative clinical cure solutions for patients with chronic hepatitis B."

Dr. Chengyong Yang, Co-founder and CSO of AusperBioStated: "The recent progress of AHB-137 is exciting, especially the Phase IIb clinical data announced at the European Association for the Study of the Liver (EASL™) Annual Meeting held in Amsterdam this month, which fully demonstrates the potential of this therapy. Thanks to the strong support from Series B+ investors, the AusperBio team will more effectively advance the clinical development strategy of AHB-137, bringing this novel clinical treatment solution to patients worldwide at an earlier date."

AusperBio Always Adheres to the Patient-Centric and High Clinical Value Innovation Concept, Committed to Reducing the Health Burden of Chronic Hepatitis B (CHB) Patients Worldwide, and Accelerating the Achievement of the Clinical Cure Goal for Hepatitis B.

AusperBio is a clinical-stage innovative drug development company operating simultaneously in China and the United States. It is committed to developing First-in-class and Best-in-class proprietary targeted delivery small nucleic acid drugs. AusperBio owns the proprietary Med-Oligo™ ASO patent technology platform, focusing on the clinical cure of chronic hepatitis B (HBV) and highly efficient targeted treatments for liver diseases, while expanding its reach into targeted small nucleic acid therapies for new targets beyond the liver. AusperBio's strategy is to combine its internationally leading Med-Oligo™ oligonucleotide technology with specific and highly efficient targeting technologies to address a wide range of currently unmet medical needs.

AHB-137 is a non-conjugated antisense oligonucleotide (ASO) with the potential to become a cornerstone for clinical cure of chronic hepatitis B. It is the first innovative drug from AusperBio's self-developed platform Med-Oligo™ to enter clinical trials, and its excellent preclinical and clinical data have gained widespread attention at the European Association for the Study of the Liver (EASL™ 2023, 2024, 2025) and the 2024 American Association for the Study of Liver Diseases (AASLD™). Currently, AHB-137 is simultaneously conducting a global multi-center Phase I clinical trial and three Phase II clinical trials in China. Through global strategic planning, it aims to accelerate the goal of achieving clinical cure for hepatitis B.